LAG3 and neoplasm: Anti-PD-L1 plus anti-CTLA-4 may also be a better option in patients with high lactate dehydrogenase, brain metastases, or mucosal melanoma, while anti-PD-1 plus anti-LAG-3 may be preferred in the elderly and perhaps patients with low tumour burden.